MedTrace Logo

Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing

NCT01892891 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-12-31

No results posted yet for this study

Summary

VBY-036 may treat or prevent nerve pain. This study aims to find the highest safe and tolerable dose of VBY-036 in healthy volunteers. Volunteers will be randomly selected to receive either a placebo or VBY-036 (30, 100, 300, 600 or 900 mg) once daily for seven days in a row.

Conditions

  • Healthy

Interventions

DRUG

VBY-036

Cathepsin S inhibitor

Sponsors & Collaborators

  • Virobay Inc.

    lead INDUSTRY

Principal Investigators

  • David B. Karpf, MD · Virobay Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01892891 on ClinicalTrials.gov